Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

3 ASCO Updates Tackle Treatment and Supportive Care Questions

November 4th 2011

ASCO endorses a Canadian agency's outlook on ovarian ablation, chemotherapy limits for stage IV lung cancer patients, and supportive care antiemetic therapies.

Dr. Langer Discusses the PARAMOUNT Study

November 2nd 2011

Dr. Corey Langer from the Abramson Cancer Center Discusses the PARAMOUNT Study

Dr. Yung Discusses Forming a Multidisciplinary Team

October 31st 2011

Dr. Rex Yung from Sidney Kimmel Comprehensive Cancer Center Discusses Forming a Multidisciplinary Team

Dr. Mills Gives Examples of Unexpected Drug Responses

October 28th 2011

Dr. Gordon Mills from MD Anderson Cancer Center Gives Examples of Unexpected Therapy Responses

Dr. Scagliotti Gives 3 Important Lung Cancer Takeaway Points

October 27th 2011

Dr. Giorgio Scagliotti from the University of Turin Gives 3 Important Lung Cancer Takeaway Points

Dr. Yung on a Paradigm Shift in Lung Cancer Treatment

October 26th 2011

Dr. Rex Yung from Sidney Kimmel Comprehensive Cancer Center on a Paradigm Shift in Lung Cancer Treatment

October 2011: Trials in Progress

October 21st 2011

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Meeting.

Dr. Scagliotti Discusses Elderly Lung Cancer Therapy

October 19th 2011

Dr. Giorgio Scagliotti from University of Turin Discusses Elderly Lung Cancer Therapy

Dr. Wakelee on the Future of Lung Cancer Adjuvant Therapy

October 18th 2011

Dr. Heather Wakelee from the Stanford Clinical Cancer Center on the Future of Lung Cancer Adjuvant Therapy

Dr. Yung on the Evolving Role of the Pulmonologist

October 17th 2011

Dr. Rex Yung from Sidney Kimmel Comprehensive Cancer Center Discusses the Evolving Role of the Pulmonologist

Dr. Wakelee on Using Lymph Nodes for Lung Cancer Staging

October 10th 2011

Dr. Heather Wakelee from Stanford Clinical Cancer Center on Using Lymph Nodes for Lung Cancer Staging

Dr. Scagliotti on Mechanisms of Resistance to EGFR TKIs

October 7th 2011

Dr. Giorgio V. Scagliotti from the University of Turin on Mechanisms of Resistance to EGFR TKIs

Dr. Langer Discusses the JMEN Maintenance Pemetrexed Trial

October 6th 2011

Dr. Corey J. Langer from Abramson Cancer Center Discusses the JMEN Maintenance Pemetrexed Trial

Dr. Kernstine on Variation in Thoracic Surgery Outcomes

October 5th 2011

Dr. Kemp Kernstine from University of Texas, Southwestern Medical Center Discusses Variation in Thoracic Surgery Outcomes

Dr. Langer on Assessing Patient Populations in Trials

October 4th 2011

Dr. Corey J. Langer from Abramson Cancer Center on Assessing Patient Populations in Clinical Trials

Making a Mark in Lung Cancer: An Interview With Roy S. Herbst, MD, PhD

October 4th 2011

Roy S. Herbst, MD, PhD, is a physician and translational researcher, whose work in developing novel, personalized therapies for lung cancer has helped drive significant changes in the way the disease is treated.

Oncogenic Signaling of the EGFR: Familiar Target Faces New Questions

October 3rd 2011

The epidermal growth factor receptor (EGFR) is the prototypical receptor tyrosine kinase (RTK) and one of the most comprehensively studied molecular targets in clinical oncology.

Welcome to UCD ChestHealth!

October 3rd 2011

Welcome to UCD ChestHealth, the official blog of UC Davis Thoracic Surgery.

Dr. Wakelee on Adjuvant Therapy Predictive Markers

September 30th 2011

Dr. Heather Wakelee from Stanford Clinical Cancer Center Discusses Adjuvant Therapy Predictive Markers

Novel PET Strategy May Predict Utility of Clinical Options

September 29th 2011

The desire to reduce the risk and severity of treatment-related toxicity by rapidly discontinuing ineffective therapy, and the increasing use of highly sensitive imaging technology.